EGFR and neoplasm: Immune checkpoint inhibitor therapies showed durable improvements in outcomes of HNSCC patients, but as for EGFR-targeted therapies, response rates are very low and tumor cells frequently acquire immunosuppressive resistance to the cytotoxic activity of immune effectors (10–13).